Eli Lilly said on Monday it sued three medical spas and online vendors for selling products claiming to contain tirzepatide, the main ingredient in its popular weight-loss medicine Zepbound, including in the form of dissolvable tablets. Pivotal Peptides says it offers research grade tirzepatide, while MangoRx sells a compounded version, both online. Lilly has accused Pivotal Peptides of selling products claiming to contain tirzepatide directly to patients without any prescription from a medical professional, despite advertising the drugs for research purposes. Lilly said it sent a cease and desist letter to Pivotal Peptides before filing the lawsuit. Eli Lilly is seeking court orders barring the vendors from selling their drugs claiming to contain tirzepatide and unspecified monetary damages.

---

Persons: Eli Lilly’s, Eli Lilly, tirzepatide, Lilly, MangoRx, drugmaker, Genesis Organizations: Lifestyle Medicine of, U.S . Food, Drug Administration, Genesis, FDA, B12 Locations: New York City, Lifestyle Medicine of Nevada, U.S, Indiana , Texas, Washington, Indianapolis